GBT Announces Participation at the H.C. Wainwright Global Life Sciences Conference
March 02 2021 - 7:30AM
Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) will
participate at the H.C. Wainwright Global Life Sciences Conference
on Tuesday, March 9, 2021. A presentation by Ted W. Love, M.D.,
president and CEO of GBT, will be available at 7:00 a.m. ET.
The presentation will be available on GBT’s website at
www.gbt.com in the Investors section. A replay will be available
for one month following the event.
About Global Blood Therapeutics
Global Blood Therapeutics (GBT) is a biopharmaceutical
company dedicated to the discovery, development, and delivery of
life-changing treatments that provide hope to underserved patient
communities. Founded in 2011, GBT is delivering on its goal to
transform the treatment and care of sickle cell disease (SCD), a
lifelong, devastating inherited blood disorder. The company has
introduced Oxbryta® (voxelotor) tablets, the first
FDA-approved treatment that directly inhibits sickle hemoglobin
polymerization, the root cause of red blood cell sickling in SCD.
GBT is also advancing its pipeline program in SCD with inclacumab,
a P-selectin inhibitor in development to address pain crises
associated with the disease, and GBT021601 (GBT601), the company’s
next generation hemoglobin S polymerization inhibitor. In addition,
GBT’s drug discovery teams are working on new targets to develop
the next wave of treatments for SCD. To learn more, please
visit www.gbt.com and follow the company on
Twitter @GBT_news.
Contact:Steven Immergut
(media)650.410.3258simmergut@gbt.com
Courtney
Roberts (investors)650.351.7881croberts@gbt.com
Global Blood Therapeutics (NASDAQ:GBT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Global Blood Therapeutics (NASDAQ:GBT)
Historical Stock Chart
From Apr 2023 to Apr 2024